NIAID AIDS Vaccine Selection Committee
Executive Summary
NIAID establishes 12-member committee to help in decisions on which potential AIDS vaccines now being tested in laboratories are "promising enough" to be tested in humans. In addition, committee will recommend minimum guidelines manufacturers must meet for eligibility for Phase I trials and for being considered for Phase II studies. Committee members include PMA VP-Medical and Regulatory Affairs John Petricciani and FDA Biological IND Division Deputy Director Janet Woodcock.